Trial Profile

CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL101) in B-cell Receptor Pathway Inhibition in CLL

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idelalisib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms CALiBRe

Most Recent Events

26 Dec 2017 The recruitment was temporarily halted in April 2016 due to the idelalisib safety alert from other trials, according to presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
12 Dec 2017 Results (n=23) assessing idelalisib in patients with chronic lymphocytic leukaemia, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
31 May 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com